Pharma BD Deal Intelligence
Valeant Revives Growth Plan With $2.6 Billion Medicis Deal. Valeant's stock rose 15 percent, its biggest gain since January 2011 and highest close on record,…
Valeant scoops up Medicis' dermatology portfolio in $2.6B buyout, leaping to the top tier of dermatology and aesthetics through another debt-funded acquisition.
Zacks Investment Research framed the closing as broadly positive: the combination created a global dermatology leader and was expected to be immediately…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Valeant acquired Medicis at $44/share cash for $2.6B (39% premium). Combined dermatology/aesthetics franchise pro forma 2012 US revenue >$1.7B. Identified $225M cost synergies within 6 months.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Valeant Pharmaceuticals International, Inc. / Medicis Pharmaceutical Corporation (this deal) | 2012 | $2.6B | 33 |
| Valeant Pharmaceuticals International, Inc. / Dow Pharmaceutical Sciences, Inc. | 2009 | $285M | 66 |
| Valeant Pharmaceuticals International, Inc. / iNova Pharmaceuticals | 2011 | $700M | 63 |
| Valeant Pharmaceuticals International, Inc. / Xcel Pharmaceuticals, Inc. | 2005 | $280M | 42 |
| Valeant Pharmaceuticals International, Inc. / Dermik Laboratories (Sanofi dermatology unit) | 2011 | $425M | 36 |
| Valeant Pharmaceuticals International, Inc. / Bausch + Lomb | 2013 | $8.7B | 36 |
| Valeant Pharmaceuticals International, Inc. / PreCision Dermatology, Inc. | 2014 | $475M | 23 |
← Browse all deals · How we score deals
More: 2012 deals · Valeant Pharmaceuticals International, Inc. deals · Dermatology deals